INTERACTION OF APELIN, ELABELA AND NITRIC OXIDE IN SCHIZOPHRENIA PATIENTS

dc.contributor.authorCatakl, Zekiye
dc.contributor.authorKaya, Hilal
dc.contributor.authorKocdemir, Esra
dc.contributor.authorUgur, Kader
dc.contributor.authorGuzel, Saadet Pilten
dc.contributor.authorYardim, Meltem
dc.contributor.authorAydin, Suleyman
dc.date.accessioned2026-08-12T17:05:45Z
dc.date.issued2020
dc.departmentFırat Üniversitesi
dc.description.abstractBackground: Apelin (APLN), elabela (ELA), and nitric oxide (NO) have effects on physiological and behavioural properties in biological systems. This study was designed to determine APLN, ELA and NO levels in schizophrenia patients and assess whether these molecules are of diagnostic value. Methods: A total of 33 schizophrenic patients and 32 age-and sex-adjusted healthy participants were included in the study. ELA, APLN and NO levels were measured using ELISA methods. Results: Although the ELA and NO levels of the patients were lower than the control group, APLN levels were higher (p = 0.039, p = 0.019, p = 0.048, respectively). There was a significant negative correlation between APLN levels and triglyceride (TG) and body mass index (BMI) levels (r = -0.426, p = < 0.001 and r = -0.330, p = 0.007, respectively). Respectively, the areas under the receiver-operating characteristic (ROC) curves of the ELA/APLN, ELA/NO and APLN/NO ratios were 0.628, 0.590 and 0.709, 95% confident intervals (CI): 0.491-0.764, 0.450-0.730 and 0.579-0.840. Conclusions: Decreased levels of ELA and NO and increased APLN levels in schizophrenia suggest that these molecules may be involved in its etiopathology. The APLN/NO ratio also seems to show promise in the diagnosis of the disease and may be used in future.
dc.identifier.doi10.2478/jomb-2019-0029
dc.identifier.endpage190
dc.identifier.issn1452-8258
dc.identifier.issn1452-8266
dc.identifier.issue2
dc.identifier.orcid0000-0003-4028-2041
dc.identifier.pmid33033451
dc.identifier.scopus2-s2.0-85095886792
dc.identifier.scopusqualityQ3
dc.identifier.startpage184
dc.identifier.urihttps://doi.org/10.2478/jomb-2019-0029
dc.identifier.urihttps://hdl.handle.net/11508/49238
dc.identifier.volume39
dc.identifier.wosWOS:000543793500008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSoc Medical Biochemists Serbia
dc.relation.ispartofJournal of Medical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectschizophrenia
dc.subjectelabela
dc.subjectapelin
dc.subjectnitric oxide
dc.titleINTERACTION OF APELIN, ELABELA AND NITRIC OXIDE IN SCHIZOPHRENIA PATIENTS
dc.typeArticle

Dosyalar